(Q38994394)

8 September 2017

title

Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients (English)

1 reference

8 September 2017

2

1 reference

8 September 2017

Serigne Lo

3

0 references

author name string

Thomas R Crookes

series ordinal

1

1 reference

8 September 2017

Martin Drummond

series ordinal

4

1 reference

8 September 2017

Andrew J Spillane

series ordinal

5

1 reference

8 September 2017

publication date

27 January 2017

1 reference

Annals of Surgical Oncology

8 September 2017

published in

1 reference

8 September 2017

volume

24

1 reference

8 September 2017

issue

5

1 reference

8 September 2017

page(s)

1378-1385

1 reference

Final version of 2009 AJCC melanoma staging and classification

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

Nomograms to predict recurrence and survival in stage IIIB and IIIC melanoma after therapeutic lymphadenectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

Limitations of lymph node ratio, evidence-based benchmarks, and the importance of a thorough lymph node dissection in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

Pathology review significantly affects diagnosis and treatment of melanoma patients: an analysis of 5011 patients treated at a melanoma treatment center

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

Adjuvant radiation therapy for high-risk nodal metastases from cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

Patterns of Recurrence in Patients with Stage IIIB/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

Improved overall survival in melanoma with combined dabrafenib and trametinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-016-5723-0

10.1245/S10434-016-5723-0

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

8 September 2017

1074241096

0 references

1 reference